ArticleDrug safety2005
Prevalence of potentially severe drug-drug interactions in ambulatory patients with dyslipidaemia receiving HMG-CoA reductase inhibitor therapy.
Alexandra E Rätz Bravo et al.PubMed ↗Publisher ↗
No numbers read from the abstract.
29 papers cite it
this paperpooled itcites it